Tirabrutinib NDA Cleared by the FDA in Relapsed/Refractory PCNSL
The Food and Drug Administration (FDA) has announced the approval of a New Drug Application (NDA) for Tirabrutinib, a significant move for relapsed/refractory PCNSL treatment.
FDA Issues Partial Clinical Hold on Lorigerlimab Trial in Gynecologic Cancers
Due to safety concerns, the Lorigerlimab trial for gynecologic cancers has been placed under a partial clinical hold by the FDA. The trial aims to enhance treatment options for patients, but patient safety remains paramount.
Refining Management of Immune-Checkpoint Inhibitor Toxicities in Melanoma
Toxicities caused by immune-checkpoint inhibitors have been a concern in melanoma treatment. The medical industry aims constantly to refine its management strategies, highlighting the need for continued evolution in this sphere.
FDA Grants Fast Track Designation to SRN-101 for Recurrent High-Grade Glioma
The FDA has granted SRN-101 a fast-track designation, signifying a significant step forward in treating recurrent high-grade glioma, one of the most aggressive forms of brain tumor.
Novel Small Molecule Shows Early Activity in Pretreated Multiple Myeloma
Much attention has centered on KTX-1001, a novel small molecule exhibiting promising early results in treating pretreated multiple myeloma. Clinical trials are ongoing, with stakeholders in the medical community observing closely for further developments.
Comparing Quality of Life Outcomes with Protons vs Photons in OPSCC
A comparative study has been initiated to evaluate quality of life outcomes between proton therapy and photon therapy in oropharyngeal cancer patients. Gathering this knowledge is crucial for optimizing patient care protocols and therapies.
